PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE FOR INJECTION DIN 02544857
Health Canada record
| Active ingredient(s) | DOXORUBICIN HYDROCHLORIDE 2 MG |
|---|---|
| Dosage form | Suspension |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01DB01 DOXORUBICIN |
| Original market date | |
| Current status date | 07-Feb-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Dr Reddy's Laboratories (UK) Limited — licence , not currently licensed, last inspection rating C (2019-02-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DOXORUBICIN HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02238389 | CAELYX | BAXTER CORPORATION | Suspension | DOXORUBICIN HYDROCHLORIDE 2 MG | Marketed |
| 02410397 | DOXORUBICIN | PFIZER CANADA ULC | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Marketed |
| 02194473 | DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | PFIZER CANADA ULC | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 150 MG | Marketed |
| 02194465 | DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | PFIZER CANADA ULC | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 50 MG | Marketed |
| 02400626 | DOXORUBICIN HYDROCHLORIDE INJECTION | OMEGA LABORATORIES LIMITED | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Approved |
| 02409275 | DOXORUBICIN HYDROCHLORIDE INJECTION | TEVA CANADA LIMITED | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Marketed |
| 02381982 | DOXORUBICIN INJECTION, BP | ACCORD HEALTHCARE INC | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Marketed |
| 02493020 | TARO-DOXORUBICIN LIPOSOMAL | TARO PHARMACEUTICALS INC | Suspension | DOXORUBICIN HYDROCHLORIDE 2 MG | Marketed |
| 02071002 | ADRIAMYCIN PFS | PFIZER CANADA ULC | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Dormant |
| 02065657 | ADRIAMYCIN RDF | PFIZER CANADA ULC | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 10 MG | Cancelled Post Market |
| 02069563 | ADRIAMYCIN RDF | PFIZER CANADA ULC | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02069555 | ADRIAMYCIN RDF | PFIZER CANADA ULC | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 50 MG | Cancelled Post Market |
| 00357391 | ADRIAMYCIN RDF INJ 10MG/VIAL | CARLO ERBA FARMITALIA SPA | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 10 MG | Cancelled Post Market |
| 00768766 | ADRIAMYCIN RDF INJ 150MG/VIAL | ADRIA LABORATORIES OF CANADA LTD. | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 00353078 | ADRIAMYCIN RDF INJ 50MG/VIAL | CARLO ERBA FARMITALIA SPA | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 50 MG | Cancelled Post Market |
| 02093057 | DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL | DAVID BULL LABORATORIES (PTY) LTD. | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 10 MG | Cancelled Post Market |
| 02093081 | DOXORUBICIN HCL FOR INJ. U.S.P. 150MG/VIAL | DAVID BULL LABORATORIES (PTY) LTD. | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02093073 | DOXORUBICIN HCL FOR INJ. U.S.P. 50MG/VIAL | DAVID BULL LABORATORIES (PTY) LTD. | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 50 MG | Cancelled Post Market |
| 02467240 | DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | PANDA PHARMACEUTICALS INC. | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 50 MG | Cancelled Pre Market |
| 02194457 | DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | PFIZER CANADA ULC | Powder For Solution | DOXORUBICIN HYDROCHLORIDE 10 MG | Cancelled Pre Market |
| 02375710 | DOXORUBICIN HYDROCHLORIDE INJECTION | SANDOZ CANADA INCORPORATED | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Cancelled Post Market |
| 02230108 | DOXORUBICIN HYDROCHLORIDE INJECTION | NOVOPHARM LIMITED | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Cancelled Post Market |
| 02413973 | DOXORUBICIN HYDROCHLORIDE INJECTION, USP | STRIDES PHARMA CANADA INC | Solution | DOXORUBICIN HYDROCHLORIDE 2 MG | Dormant |
| 02245015 | MYOCET | SOPHERION THERAPEUTICS LLC | Liposomes | DOXORUBICIN HYDROCHLORIDE 2 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32655 | 2024-02-07 | Abbreviated New Drug Submission (ANDS) |
International API supply for DOXORUBICIN HYDROCHLORIDE
10 valid EDQM Certificates of Suitability from 10 holders. 11 active FDA Drug Master Files.
Request a quote for PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE FOR INJECTION